On April 2, 2012, Obagi Medical Products, Inc. OMPI (the “Company”
or “Obagi”) announced that the Obagi Board of Directors had received an
unsolicited letter from Merz Pharma offering $22 per share cash to acquire the
Company, and the Obagi Board of Directors will evaluate Merz Pharma's offer
and the merger terms consistent with its fiduciary and legal duties. The Obagi
Board of Directors realizes that time is of the essence in this matter.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in